Profile data is unavailable for this security.
About the company
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
- Revenue in USD (TTM)0.00
- Net income in USD-119.67m
- Incorporated2019
- Employees28.00
- LocationMineralys Therapeutics Inc150 N. Radnor Chester Road, Suite F200RADNOR 19087United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://mineralystx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Humacyte Inc | 0.00 | -139.66m | 690.16m | 183.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | -0.237 | 0.00 | -- | -- | 0.00 | -91.17 | -- | -100.75 | -- | -- | -- | -- | -- | -- | -40.08 | -- | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Arbutus Biopharma Corp | 6.74m | -76.70m | 706.80m | 73.00 | -- | 6.61 | -- | 104.84 | -0.4259 | -0.4259 | 0.0374 | 0.5643 | 0.0451 | -- | 3.57 | 92,356.16 | -51.29 | -52.62 | -59.50 | -58.11 | -- | -- | -1,137.65 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Tourmaline Bio Inc | 0.00 | -48.85m | 726.16m | 44.00 | -- | 2.26 | -- | -- | -1.68 | -1.68 | 0.00 | 12.52 | 0.00 | -- | -- | 0.00 | -20.37 | -- | -21.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -110.78m | 726.59m | 107.00 | -- | 2.30 | -- | -- | -1.76 | -1.76 | 0.00 | 4.47 | 0.00 | -- | -- | 0.00 | -35.69 | -33.92 | -37.77 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| Olema Pharmaceuticals Inc | 0.00 | -109.63m | 728.43m | 80.00 | -- | 3.21 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Stoke Therapeutics Inc | 16.74m | -105.46m | 731.47m | 110.00 | -- | 3.15 | -- | 43.69 | -2.10 | -2.10 | 0.3294 | 4.38 | 0.0628 | -- | 42.55 | 152,209.10 | -39.56 | -31.62 | -46.04 | -33.92 | -- | -- | -629.86 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| Annexon Inc | 0.00 | -115.16m | 736.41m | 71.00 | -- | 2.04 | -- | -- | -1.22 | -1.22 | 0.00 | 3.42 | 0.00 | -- | -- | 0.00 | -36.04 | -44.06 | -38.13 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| Mineralys Therapeutics Inc | 0.00 | -119.67m | 741.92m | 28.00 | -- | 2.56 | -- | -- | -2.71 | -2.71 | 0.00 | 5.84 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Entrada Therapeutics Inc | 215.23m | 54.95m | 744.28m | 177.00 | 12.48 | 1.76 | 12.73 | 3.46 | 1.59 | 1.59 | 5.97 | 11.30 | 0.4141 | -- | 56.43 | 1,353,660.00 | 10.57 | -- | 13.68 | -- | -- | -- | 25.53 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| Perspective Therapeutics Inc | -1.87m | -49.02m | 747.77m | 116.00 | -- | 2.19 | -- | -- | -1.39 | -1.75 | -0.0437 | 5.06 | -0.0074 | -- | -- | -16,086.21 | -19.37 | -- | -20.14 | -- | -- | -- | -- | -- | -- | -- | 0.005 | -- | -- | -- | -- | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 378.42m | -2.46m | 763.55m | 267.00 | -- | -- | -- | 2.02 | -0.016 | -0.016 | 2.39 | -1.95 | 0.8284 | -- | 3.77 | 1,417,296.00 | -0.6832 | -4.54 | -1.07 | -5.20 | -- | -- | -0.8248 | -7.81 | -- | 3.88 | 2.08 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| IGM Biosciences Inc | 2.92m | -219.84m | 764.02m | 198.00 | -- | 9.70 | -- | 261.83 | -3.65 | -3.65 | 0.0484 | 1.33 | 0.0075 | -- | -- | 13,026.79 | -56.45 | -44.66 | -63.54 | -48.20 | -- | -- | -7,534.03 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Exscientia PLC (ADR) | 27.05m | -166.78m | 770.36m | 483.00 | -- | 1.99 | -- | 28.48 | -1.31 | -1.31 | 0.2129 | 3.00 | 0.042 | -- | 26.88 | 56,008.21 | -25.87 | -- | -29.52 | -- | -32.45 | -- | -616.50 | -- | -- | -- | 0.0674 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| BIOAGE Labs Inc | 0.00 | -62.16m | 774.57m | 58.00 | -- | -- | -- | -- | -1.82 | -1.82 | 0.00 | 4.26 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -4.99 | 0.0724 | -- | -- | -- | -60.75 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -41.53m | 775.88m | 40.00 | -- | 5.98 | -- | -- | -0.5012 | -0.5012 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -27.75 | -40.04 | -30.03 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| MBX Biosciences Inc | 0.00 | -47.20m | 785.31m | 36.00 | -- | -- | -- | -- | -1.48 | -1.48 | 0.00 | 1.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.60 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Mineralys Therapeutics Inc's reporting currency: US Dollar USD
31.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Jun 2024 | 4.85m | 9.76% |
| HBM Partners AG (Investment Management)as of 31 Dec 2023 | 2.25m | 4.52% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.85m | 3.72% |
| Franklin Advisers, Inc.as of 30 Jun 2024 | 1.48m | 2.98% |
| Laurion Capital Management LPas of 30 Jun 2024 | 1.46m | 2.93% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.19m | 2.40% |
| Caligan Partners LPas of 30 Jun 2024 | 745.76k | 1.50% |
| American Century Investment Management, Inc.as of 30 Jun 2024 | 743.14k | 1.49% |
| Jennison Associates LLCas of 30 Sep 2024 | 696.28k | 1.40% |
| Octagon Capital Advisors LPas of 30 Jun 2024 | 600.00k | 1.21% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
